August 6, 2012
American Medical News
This article discusses Assn. for Molecular Pathology v. U.S. Patent and Trademark Office et al., and looks to legal experts on their thoughts regarding what the "appeals judges appeared to show their hand during re-arguments." Finnegan senior counsel, David S. Forman, Ph.D., provided commentary. Dr. Forman stated he would be “very surprised if the federal circuit rules substantially different from the first decision.” He also said, “It is probable that it’ll go back to the Supreme Court because it’s so controversial. Because of Prometheus, there is more uncertainty as to what the Supreme Court might do with this.”
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Commentary
New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret
September 21, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.